Eli Lilly and Company

Hanall Biopharma Co., Ltd.

Immunovant Sciences Gmbh

William Louis Macias

Eunsun Kim

Hyeakyung Ahn

Seungkook Park

Minho Yoon

Haeyoung Yong

Mijin Jung

Su Liang

Hyeeun Shim

The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.

Anti-FcRn antibody or antigen binding fragment thereof with improved stability

A method is disclosed for the treatment of non-rheumatoid arthritis by administering to a mammal in need thereof a therapeutically effective amount of an sPLA inhibitor.

Method for treatment of non-rheumatoid arthritis

A method is disclosed for the treatment of cystic fibrosis by administering to a human in need thereof a therapeutically effective amount of an sPLA inhibitor, such as a 1H-indole-3-glyoxylamide.

Method for the treatment of cystic fibrosis

The present invention is directed to compounds for treating inflammatory bowel disease. More specifically, the present invention is directed to 1H-indole-3-glyoxyamide compounds a sPLA inhibitors for treating inflammatory bowel disease.

SPLA2 inhibitor compounds for treatment of disease

A method is disclosed for the treatment of chronic bronchitis by administering to a mammal in need thereof a therapeutically effective amount of a 1H-indole-3-glyoxylamide compound.

Growing community of inventors

Indianapolis, IN, United States of America

William Louis Macias